drugset / Trial / NCT02082769

Safety and Efficacy of Oral Febuxostat in Subjects With Gout

NCT02082769

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare febuxostat allopurinol in subjects with gout.

Timeline

Start
2011-07
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Allopurinol Small molecule 100 mg Oral
Subject Febuxostat Small molecule 40 mg Oral
Subject Febuxostat Small molecule 80 mg Oral

Indications